Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

Author： Lee W.C. Conner C. Hammer M.

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.5, 2011-05, pp. : 897-906

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US**

By Tunis Sandra L. Minshall Michael E. St. Charles Meaghan Pandya Bhavik J. Baran Robert W.

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3085-3096

Informa Healthcare

Access to resources Recommend Favorite

Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus

By Derosa Giuseppe Salvadeo Sibilla AT Cicero Arrigo FG

Therapy, Vol. 3, Iss. 5, 2006-09 ,pp. : 559-569

Future Medicine

Access to resources Recommend Favorite

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

By McEwan Phil Poole Chris D. Tetlow Tony Holmes Paul Currie Craig J.

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 21-31

Informa Healthcare

Access to resources Recommend Favorite

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK

By McEwan Phil Poole Chris D. Tetlow Tony Holmes Paul Currie Craig J.

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-02 ,pp. : 7-19

Informa Healthcare

Access to resources Recommend Favorite